Category: Baystreet Newswire
Date: Tuesday, September 24, 2013
SHERWOOD, OR, September 24, 2013 - (Accesswire) - Entia Biosciences (Entia; OTCQB: ERGO), a food science biotechnology company and emerging leader in the field of Nutrigenomics, has engaged BioCheck Inc., of Foster City, California to develop a family of monoclonal and polyclonal antibodies and enzyme-linked immunosorbent assays (ELISA) that can be used to diagnose deficiencies of important dietary nutrients in human tissue, serum, plasma, and urine. The companies will initially focus on the development of proprietary antibodies and assays for L-Ergothioneine (Ergo) and to Leukocyte 8-Hydroxydeoxyguanosine (8-OHdG). When approved for use, these new tests are expected help physicians cost-effectively measure changes in these biomarkers and determine if Entia’s medical foods will be an appropriate and beneficial therapy for patients.
Ergo is a potent amino acid and electron donating antioxidant that is acquired exclusively from the diet and carried by a unique and specific transporter (human gene symbol SLC22A4) into cells throughout the body that are fighting damage and death from oxidative stress and toxic free radical reactions. Drs. Paul and Snyder of Johns Hopkins University School of Medicine have suggested that Ergo is as potent as glutathione and because of its dietary origin and the toxicity associated with its depletion, it may represent a new vitamin whose physiologic roles include antioxidant cytoprotection. These doctors further believe that the high density of Ergo within mitochondria implies a unique role in protecting mitochondrial DNA from damage induced by free radicals and reactive oxygen species (Paul & Snyder, 2009). Entia acquired the world-wide exclusive diagnostic and therapeutic rights to the Ergo Transporter (ETT) from the University of Cologne (Germany) in 2010 and has filed patents on the use of Ergo in the treatment of anemia, diabetes, auto-immune diseases, and neurodegenerative diseases.
8-OHdG is an indicator of oxidative stress, impaired metabolism, and mitochondrial dysfunction and is a biomarker that is excised during repair of oxidative damage to DNA. Studies have observed increases in 8-OHdG levels in anemia (Honda, 2000), diabetes (Wu, 2004), stroke and several important neurodegenerative diseases (Mariani, 2005), including mild cognitive impairment, Parkinson's disease, amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Huntington’s disease (Long, 2012), and Autism (Kern, 2013).
"The unique proprietary technologies of Entia Biosciences and BioCheck will be used to create a ‘Companion Diagnostic’ platform that will provide important biological and/or clinical information, enable better decisions in the application of medical foods in personalized medicine, and improve the early intervention and prevention of serious medical conditions that are currently running unchecked," stated Marvin S. Hausman MD, CEO, Entia Biosciences. “Dr. Chen and the team at BioCheck have been involved in the development of a number of widely used diagnostics that have been approved for marketing by the FDA, including the first rapid pregnancy test, and we are excited that they share our vision for the use of bionutrients to regulate the onset, progression, and amelioration of debilitating diseases.”